Provided herein are synthetic compounds useful for inhibiting bacterial growth and uses thereof. Also provided are pharmaceutical compositions. The compounds and pharmaceutical compositions are useful for inhibiting growth of a bacterium or treating or preventing a bacterial infection.

Methods and devices for coating a respiratory system and thereby protecting from or killing viral, bacterial, or viral and bacterial infections are disclosed. An active compound that is a virucide, a bactericide, or both, is vaporized by a vaporizing device and inhaled into the respiratory system where the active compound coats the respiratory system.

Methods and devices for coating a respiratory system and thereby protecting from or killing viral, bacterial, or viral and bacterial infections are disclosed. An active compound that is a virucide, a bactericide, or both, is vaporized by a vaporizing device and inhaled into the respiratory system where the active compound coats the respiratory system.

An object of the present invention is to provide a measure for treating or preventing a disease or condition that involves AMPK dysregulation, particularly a cancer. The present invention provides a combination therapy using a compound presented by formula (I), a pharmaceutically acceptable salt or a solvate thereof with an immune checkpoint inhibitor.

An object of the present invention is to provide a measure for treating or preventing a disease or condition that involves AMPK dysregulation, particularly a cancer. The present invention provides a combination therapy using a compound presented by formula (I), a pharmaceutically acceptable salt or a solvate thereof with an immune checkpoint inhibitor.

The compound

##STR00001##

wherein R1 is selected from amongst: H, Me, OH; R2 is selected from amongst: H, OH, Me, t-Bu, Et, OMe, Pr, Allyl; R3 is selected from amongst: H, OH, Me, Cl, F; R4 is selected from amongst: H, Me, Ome, t-Bu, Cl; R5 is selected from amongst: H, OH, Me, OMe; R6 is selected from amongst: H, Me, OH, OMe; R7 is selected from the group consisting of: H, Me, OMe, t-Bu, Cl; R8 is selected from the group consisting of: OH, Me, H, F; R9 is selected from the group consisting of; OH, Me, H, t-Bu, Et, OMe, Pr, Allyl; R10 is selected from the group consisting of: H, Me, OH; and X is either absent or is selected from the group consisting of:

##STR00002##

, CO, CH.sub.2,

##STR00003##

, for use in a method for treating pathologies mediated by the interaction of the uPAR/FPRs receptors.

The compound

##STR00001##

wherein R1 is selected from amongst: H, Me, OH; R2 is selected from amongst: H, OH, Me, t-Bu, Et, OMe, Pr, Allyl; R3 is selected from amongst: H, OH, Me, Cl, F; R4 is selected from amongst: H, Me, Ome, t-Bu, Cl; R5 is selected from amongst: H, OH, Me, OMe; R6 is selected from amongst: H, Me, OH, OMe; R7 is selected from the group consisting of: H, Me, OMe, t-Bu, Cl; R8 is selected from the group consisting of: OH, Me, H, F; R9 is selected from the group consisting of; OH, Me, H, t-Bu, Et, OMe, Pr, Allyl; R10 is selected from the group consisting of: H, Me, OH; and X is either absent or is selected from the group consisting of:

##STR00002##

, CO, CH.sub.2,

##STR00003##

, for use in a method for treating pathologies mediated by the interaction of the uPAR/FPRs receptors.

The present invention relates to compositions comprising thymol and at least one amino acid for use in the preventive and/or curative treatment of inflammatory or functional diseases or symptoms of the intestinal tract by modulating the receptors and/or enzymes of the endocannabinoid system in mammalian or non-mammalian monogastric subjects, such as human subjects, pigs, poultry animals, fish or crustaceans.

The present invention relates to compositions comprising thymol and at least one amino acid for use in the preventive and/or curative treatment of inflammatory or functional diseases or symptoms of the intestinal tract by modulating the receptors and/or enzymes of the endocannabinoid system in mammalian or non-mammalian monogastric subjects, such as human subjects, pigs, poultry animals, fish or crustaceans.

A compound of formula (I) for use in a method for treatment of pulmonary fibrosis in a human including administering, with a dry powder inhaler, once-a-day to the narrowest parts of the lung tissue of the human an amount of the compound of formula (I) effective to treat the pulmonary fibrosis.